Dataset Information

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6^th annual ImmunoRad conference.

ABSTRACT: Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.

SUBMITTER: Gregucci F

PROVIDER: S-EPMC10286673 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6<sup>th</sup> annual ImmunoRad conference.

Gregucci Fabiana F Spada Sheila S Barcellos-Hoff Mary Helen MH Bhardwaj Nina N Chan Wah Hak Charleen C Fiorentino Alba A Guha Chandan C Guzman Monica L ML Harrington Kevin K Herrera Fernanda G FG Honeychurch Jamie J Hong Theodore T Iturri Lorea L Jaffee Elisabeth E Karam Sana D SD Knott Simon R V SRV Koumenis Constantinos C Lyden David D Marciscano Ariel E AE Melcher Alan A Mondini Michele M Mondino Anna A Morris Zachary S ZS Pitroda Sean S Quezada Sergio A SA Santambrogio Laura L Shiao Stephen S Stagg John J Telarovic Irma I Timmerman Robert R Vozenin Marie-Catherine MC Weichselbaum Ralph R Welsh James J Wilkins Anna A Xu Chris C Zappasodi Roberta R Zou Weiping W Bobard Alexandre A Demaria Sandra S Galluzzi Lorenzo L Deutsch Eric E Formenti Silvia C SC

Oncoimmunology 20230621 1

Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gat ...[more]

PMID: 37363104

Similar Datasets

Project description:Thyroglobulin (Tg) protein is synthesised uniquely by thyroid tissue and is measured as a post-operative differentiated thyroid cancer (DTC) tumour-marker. Tg autoantibodies (TgAb), present in ?20 percent of DTC patients, interfere with Tg immunometric assay (IMA) measurements causing falsely low/undetectable serum Tg values. Tg radioimmunoassay (RIA) methodology appears resistant to such interferences but has limited availability, whereas new Tg mass-spectrometry methods have inferior sensitivity and unproven clinical value. When present, TgAb concentrations respond to changes in thyroid tissue mass. Thus, when Tg IMA measurements are compromised by the presence of TgAb the TgAb trend can serve as a surrogate DTC tumour-marker. Unfortunately, both physiologic and technical factors impact the interpretation of Tg and TgAb used as DTC tumour-markers. Serum Tg Testing Circulating Tg concentrations change in response to thyroid tissue mass, injury (surgery, biopsy or radioiodine) and the degree of TSH stimulation. Technical factors (Tg assay sensitivity, specificity and interferences) additionally impact the clinical utility of Tg testing. Specifically, new 2nd generation Tg IMAs (functional sensitivities ? 0.1 ?g/L) now mostly obviate the need for expensive recombinant human TSH(rhTSH)-stimulated Tg testing. Tg molecular heterogeneity remains responsible for two-fold between-method differences in Tg values that preclude switching methods and TgAb interference remains especially problematic. Serum TgAb Testing Reliable TgAb testing is critical for authenticating that Tg IMA measurements are not compromised by interference. Unfortunately, TgAb methodologies vary widely in sensitivity, specificity and the absolute values they report, necessitating that TgAb concentrations be monitored using the same method. Furthermore, adopting the manufacturer’s TgAb cut-off value to define a ‘detectable’ TgAb results in falsely classifying sera as TgAb-negative, because manufacturers’ cut-offs are set to diagnose thyroid autoimmunity and not to detect TgAb interference.

Dataset Information

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6^th annual ImmunoRad conference.

Publications

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6<sup>th</sup> annual ImmunoRad conference.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.

Publications

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6&lt;sup&gt;th&lt;/sup&gt; annual ImmunoRad conference.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6^th annual ImmunoRad conference.

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6<sup>th</sup> annual ImmunoRad conference.